- Details
- David Penson provides insights on his keynote lecture from ASCO GU 2020 in this conversation with Alicia Morgans. He focuses on recognizing that methods of effectively measuring a patient’s quality of life are not easy to define. In addition to the physical, psychological and social experiences that contribute to a patient’s quality of life, Dr. Penson argues the growing burden of financial resour...
|
- Details
- Ashish Kamat welcomes a fellow bladder cancer colleague, John Taylor, to discuss international research partnerships among clinicians and organizations. Taylor and Kamat both were essential in the founding of the Leo & Anne Albert Institute of Bladder Cancer Cancer and Research, which provides a platform for clinicians to collaborate on the most recent bladder cancer research. Dr. Taylor also shar...
|
- Details
- Matt Galsky joins Ashish Kamat at ASCO GU 2020 to discuss the most recent advancements in the field of adjuvant therapy in bladder cancer. Together they discuss immune checkpoint blockade therapy in bladder cancer, how to factor in prior therapy for patients considering adjuvant therapy, and Dr. Galsky’s personal research on pathologic complete response. Biography: Matthew Galsky, MD Director of G...
|
- Details
- Alicia Morgans and Neal Shore discuss the clinical implications of the CARD study, a phase 4 study demonstrating the first third-line treatment for metastatic castration-resistant prostate cancer (mCRPC), that prolonged overall survival with cabazitaxel as compared to treatment with a second AR targeted agent in men who had docetaxel and the alternative AR targeted agent in their prior treatment h...
|
- Details
- Joining Ashish Kamat is Arjun Balar, both experts in the field of bladder cancer and each closely involved with the FDA approval of pembrolizumab in the BCG-unresponsive bladder cancer population. Dr. Balar outlines the history of the drug, how the study which led to the FDA approval in NMIBC was designed. Dr. Balar also expands in his approach to counseling his patients who are considering pembro...
|
- Details
- Ashish Kamat sits down with Petros Grivas to discuss the recent advances and clinical trials in second and third-line therapies in metastatic urothelial cancer. Biographies: Petros Grivas, MD, PhD , Associate Professor, Clinical Director of Genitourinary Cancers Program, University of Washington, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center Ashish Kamat, MD,...
|
- Details
- Alicia Morgans is joined by Felix Feng to discuss his recent presentation on a new analysis from the Phase III RTOG 9601 trial. They discuss the application of using Decipher, a test based on gene expression profiles in primary tumors in prostate cancer, which adds significantly to identifying the men with the most aggressive disease. It drives the discussion to when we adopt genomic biomarkers in...
|
- Details
- Sima Porten joins Ashish Kamat in a conversation regarding post-operative care of radical cystectomy patients. As someone who has first-hand experience in the difficulty of a culture shift in this process, Dr. Porten outlines how clinics can successfully adopt the ERAS protocol for radical cystectomy, emphasizing the importance of its effectiveness driving a team mentality in the clinical setting....
|
- Details
- In this discussion on the CARD trial with Alicia Morgans, Karim Fizazi discusses the study design, rationale, treatment strategy, and quality of life endpoints from the ASCO GU 2020 presentation: Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer from the CARD study. The objective of the QoL analysis was focused on three parti...
|
- Details
- Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...
|
